Auto Amazon Links: No products found.
GLP-1 weight loss injections have emerged as a major breakthrough in medical treatments during the past decade. Experts in science and healthcare highlight their significant role in addressing the increasingly urgent global obesity epidemic. Currently, over 50 clinical trials are investigating new medications in this category, raising important questions about how obesity management might evolve in the near future.
A pivotal moment came in February 2021 when an international research team published findings that would revolutionize approaches to weight loss. Led by Professor John Wilding of the University of Liverpool and Professor Bob Kushner from the United States, their two-year trial studied semaglutide—the key component in Wegovy—and found that participants lost up to 15% of their body weight within 68 weeks. As Wilding explained, “The people who were taking the placebo injections, who were getting exactly the same support from the dieticians and everything only lost about 2.5% of their body weight.” He emphasized the novelty of this achievement: “We’d never seen that with medicine before.” Shortly after these results were published, Wegovy received approval in the US, launching a multi-billion-pound industry centered on GLP-1 drugs.
GLP-1 itself is one of many hormones naturally produced in the gut that help regulate appetite, partly by sending signals to the brain indicating fullness. Its existence has been known since the 1980s, although it was initially considered primarily for treating type-2 diabetes due to its role in stimulating insulin secretion. During the 1990s, researchers at Imperial College London observed that injecting rats with GLP-1 reduced their appetite, a finding that intrigued Wilding but whose significance was not fully appreciated at the time. The challenging aspect has been that natural GLP-1 breaks down very quickly in the body—within one to two minutes—limiting its therapeutic use for weight loss.
Over time, scientists developed synthetic versions of GLP-1 receptor agonists that could last longer. In the early 2000s, a New York-based team created a compound lasting twelve hours, enabling practical patient use. Drug companies such as Novo Nordisk and Eli Lilly subsequently produced weekly injectable formulations, including well-known brands like Ozempic, Saxenda, Wegovy, and Mounjaro. Many patients report life-changing results. For example, David Hynd, a delivery driver from St Helens with a thyroid condition complicating weight loss, has lost around 25kg following nearly a year on Mounjaro. David recounted his experience: “In the first month that I started taking Mounjaro I lost nearly a stone. When you see that coming off you in a month it’s just a complete eye opener. So obviously you keep going.” Before starting treatment, he suffered from multiple health problems, including heart failure and sleep apnea, and had unsuccessfully tried various diets. He noted a significant change in his appetite and preferences, saying, “I just don’t eat biscuits now, I don’t eat the things I normally had. The first couple of months I was just eating salads and chicken breast but really, really enjoying it. I still enjoy it now.”
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.